Rankings / Cognitive — Prescription Stimulants
Methylphenidate / phenidate stimulants
Cognitive · Prescription stimulant / dopamine-norepinephrine reuptake inhibitor
Tier C
High-risk evidence profile
Bottom line
Read Off Label grades Methylphenidate / phenidate stimulants as C (4.9/10) based on moderate evidence, med benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: methylphenidate, ethylphenidate, 4-fluoromethylphenidate and methylnaphthidate.
Studied, labeled, or reported-use context: Clinical ADHD dosing varies by formulation; no enhancement dose — Rx Schedule II in US for methylphenidate; analog legality varies; WADA S6 prohibited in competition; not individualized guidance.
What the evidence says
WADA coverage: methylphenidate, ethylphenidate, 4-fluoromethylphenidate and methylnaphthidate. Added because this stimulant family was not represented by the existing amphetamine/modafinil rows.
Mechanism
Methylphenidate and analogs increase catecholamine signaling, improving ADHD symptoms and wakeful task focus; healthy-user cognitive enhancement is smaller and context-dependent.
Studied, labeled, or reported dose & route
Clinical ADHD dosing varies by formulation; no enhancement dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Methylphenidate / phenidate stimulants's effects?
- Read Off Label rates the evidence for Methylphenidate / phenidate stimulants as Moderate and the benefit magnitude as med, producing an overall grade of C (4.9/10). WADA coverage: methylphenidate, ethylphenidate, 4-fluoromethylphenidate and methylnaphthidate.
- What safety findings are reported for Methylphenidate / phenidate stimulants?
- Methylphenidate / phenidate stimulants has a med-high risk profile in the database. Med-High (BP/HR elevation, appetite/sleep disruption, anxiety, misuse/dependence risk) Legal status: Rx Schedule II in US for methylphenidate; analog legality varies; WADA S6 prohibited in competition.
- What does the low Safety score for Methylphenidate / phenidate stimulants represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Methylphenidate / phenidate stimulants?
- Clinical ADHD dosing varies by formulation; no enhancement dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Methylphenidate / phenidate stimulants work?
- Methylphenidate and analogs increase catecholamine signaling, improving ADHD symptoms and wakeful task focus; healthy-user cognitive enhancement is smaller and context-dependent.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.